News | January 26, 2024
Syngene Q3 FY 24 PAT up 4% to Rs 115 Cr
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
Atlas AI combines NVIDIA BioNeMo cloud APIs for intelligent chemical and protein design
Collaboration provides AstraZeneca with exclusive rights to Omniose’s proprietary bioconjugation platform to explore potential vaccines for a broad range of bacterial pathogens
Five batches across four programs of Biocon Academy participated in the graduation ceremony
Expansion of presence in India with electrical safety, electromagnetic compatibility and medical device biocompatibility, toxicity and microbiology testing and certification services
The Regional Reference Laboratory in Chennai is equipped with cutting-edge diagnostic technologies
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
New Molecular biology lab launched, AIIA increased its work scope in form of MoUs
The campus in Genome Valley will provide services in discovery chemistry & discovery biology, safety toxicology, bioanalytical services and formulation development to global pharmaceutical companies
Subscribe To Our Newsletter & Stay Updated
